Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00078338
Status:
COMPLETED
Last Update Posted:
2018-06-27
First Post:
2004-02-23
Brief Title:
Rebif Versus Copaxone in the Treatment of Relapsing Remitting Multiple Sclerosis
Sponsor:
EMD Serono
Organization:
EMD Serono
Study Overview
Official Title:
Phase IV Multicenter Open Label Randomized Study of Rebif 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to assess the clinical efficacy of Rebif 44 microgram mcg three times per week compared with Copaxone 20 milligram mg daily in subjects with relapsing Multiple Sclerosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None